Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 MannKind Ends Afrezza License with Sanofi | Contract Pharma

What are you searching for?

Sign in
Breaking News

MannKind Ends Afrezza License with Sanofi

Will transition development and commercialization to MannKind

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

MannKind Corp. has terminated its license and collaboration agreement with Sanofi-aventis U.S. for the development and commercialization of Afrezza (insulin human) Inhalation Powder. The companies will transition the development and commercialization of Afrezza from Sanofi to MannKind within 180 days.
 
MannKind is reviewing its strategic options for Afrezza as a result of the termination of the Sanofi collaboration.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics